Department of Radiology, Ladoke Akintola University of Technology Teaching Hospital, Osogbo, Nigeria.
Department of Radiology, Obafemi Awolowo Teaching Hospital Complex, Ile-Ife, Osun State, Nigeria.
Niger Postgrad Med J. 2021 Jul-Sep;28(3):193-197. doi: 10.4103/npmj.npmj_577_21.
This study was carried out to evaluate the efficacy of the combined use of oral naproxen and cervical lidocaine spray during hysterosalpingography (HSG) compared to the use of oral naproxen or cervical lidocaine spray alone. Materials and Methods: This prospective randomised controlled study was carried out using a total of 240 patients who were randomly assigned to four groups. Group 1 received cervical lidocaine spray only, Group 2 received oral naproxen only, Group 3 received cervical lidocaine spray and naproxen tablet, whereas Group 4 was the control group. A visual analogue scale was used for subjective pain assessment at three pre-defined steps.
The mean pain scores of the patients in each of the four groups are Group 1 (3.6 ± 2.0, 5.1 ± 1.8, 5.8 ± 2.2); Group 2 (2.7 ± 1.4, 3.6 ± 2.0 and 3.9 ± 1.9); Group 3 (2.8 ± 1.5, 3.4 ± 2.0 and 4.2 ± 2.3); Group 4 (4.7 ± 1.7, 5.9 ± 1.7 and 5.3 ± 1.7) at T1, T2 and T3, respectively. Pain perception was statistically significantly reduced by naproxen and combined naproxen plus lidocaine spray at all the stages of HSG while cervical lidocaine spray had a statistically significant reduction in pain perception only during cervical instrumentation.
Oral naproxen and combined naproxen plus cervical lidocaine spray were effective in reducing HSG-associated pain during all the stages of HSG. However, combined oral naproxen and lidocaine spray did not show superior efficacy over oral naproxen alone. Cervical lidocaine spray was not an effective method.
本研究旨在评估在子宫输卵管造影术(HSG)中联合使用口服萘普生和宫颈利多卡因喷雾的疗效,与单独使用口服萘普生或宫颈利多卡因喷雾相比。
本前瞻性随机对照研究共纳入 240 例患者,随机分为四组。第 1 组仅接受宫颈利多卡因喷雾,第 2 组仅接受口服萘普生,第 3 组接受宫颈利多卡因喷雾和萘普生片,第 4 组为对照组。使用视觉模拟评分法在三个预先定义的步骤对主观疼痛进行评估。
四组患者的平均疼痛评分分别为:第 1 组(3.6 ± 2.0、5.1 ± 1.8、5.8 ± 2.2);第 2 组(2.7 ± 1.4、3.6 ± 2.0 和 3.9 ± 1.9);第 3 组(2.8 ± 1.5、3.4 ± 2.0 和 4.2 ± 2.3);第 4 组(4.7 ± 1.7、5.9 ± 1.7 和 5.3 ± 1.7)在 T1、T2 和 T3 时。在 HSG 的所有阶段,萘普生和联合使用萘普生加利多卡因喷雾均可显著减轻疼痛感知,而宫颈利多卡因喷雾仅在宫颈器械操作时可显著减轻疼痛感知。
口服萘普生和联合使用萘普生加宫颈利多卡因喷雾可有效减轻 HSG 过程中的疼痛,而联合使用萘普生加利多卡因喷雾与单独使用口服萘普生相比,并未显示出更优的疗效。宫颈利多卡因喷雾不是一种有效的方法。